BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.358
+0.014 (4.07%)
At close: Jan 21, 2025, 4:00 PM
0.360
+0.002 (0.56%)
After-hours: Jan 21, 2025, 7:37 PM EST
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $214.00K in the quarter ending September 30, 2024, a decrease of -37.24%. This brings the company's revenue in the last twelve months to $2.28M, up 83.25% year-over-year. In the year 2023, BioXcel Therapeutics had annual revenue of $1.38M with 268.00% growth.
Revenue (ttm)
$2.28M
Revenue Growth
+83.25%
P/S Ratio
5.62
Revenue / Employee
$30,757
Employees
74
Market Cap
17.77M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
BTAI News
- 2 months ago - BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics to Present at ThinkEquity Conference - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - GlobeNewsWire
- 4 months ago - BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - GlobeNewsWire
- 4 months ago - BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire